



Corrigendum

Corrigendum to “In vitro susceptibility to the pro-apoptotic effects of TIMP-3 gene delivery translates to greater in vivo efficacy versus gene delivery for TIMPs-1 or -2” [Lung Cancer 53 (3) (September 2006) 273–284]



Katherine M. Finan^a, Greg Hodge^{a,b,c}, Ann M. Reynolds^a, Sandra Hodge^a,
Mark D. Holmes^{a,c}, Andrew H. Baker^d, Paul N. Reynolds^{a,c,*}

^a Department of Thoracic Medicine and Lung Research Laboratory, Royal Adelaide Hospital and Hanson Institute Adelaide, South Australia 5000, Australia

^b Department of Haematology, Women's and Children's Hospital, Adelaide, South Australia 5000, Australia

^c University of Adelaide, Adelaide, South Australia 5000, Australia

^d University of Glasgow, Glasgow, UK

The authors regret that Fig. 8 was noted to inadvertently contain duplicate panels that were labeled as different treatment groups. A correct panel is provided: Effect of AdCMVTIMP3 on apoptosis by TUNEL assay. (1-a) PBS, (1-b) AdCMVLuc, (1-c) AdCMVTIMP-1, (1-d) AdCMVTIMP-2, (1-e) AdCMVTIMP-3.




Fig. 8

The authors would like to apologise for any inconvenience caused.

DOI of original article: <http://dx.doi.org/10.1016/j.lungcan.2006.06.006>.

* Corresponding author at: Department of Thoracic Medicine and Lung Research Laboratory, Royal Adelaide Hospital and Hanson Institute Adelaide, South Australia 5000, Australia.

E-mail address: paul.reynolds@adelaide.edu.au (P.N. Reynolds).